<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Polish IP &#38; IT law - copyright trademark computer internet telecomm &#187; medicinal product</title>
	<atom:link href="http://rychlicki.net/en/issue/trademark-law/medicinal-product/feed/" rel="self" type="application/rss+xml" />
	<link>http://rychlicki.net/en</link>
	<description>Tomasz Rychlicki Intellectual Property Law Internet Law IT Law Computer Law</description>
	<lastBuildDate>Mon, 30 Jan 2012 13:02:39 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Trade mark law, case II GSK 839/10</title>
		<link>http://rychlicki.net/en/2012/01/17/7463/</link>
		<comments>http://rychlicki.net/en/2012/01/17/7463/#comments</comments>
		<pubDate>Tue, 17 Jan 2012 13:03:47 +0000</pubDate>
		<dc:creator>Tomasz Rychlicki</dc:creator>
				<category><![CDATA[Art. 154 IPL]]></category>
		<category><![CDATA[Art. 169(1)(i) IPL]]></category>
		<category><![CDATA[Art. 169(2) IPL]]></category>
		<category><![CDATA[Art. 169(6) IPL]]></category>
		<category><![CDATA[Art. 170 IPL]]></category>
		<category><![CDATA[medicinal product]]></category>
		<category><![CDATA[non-use]]></category>
		<category><![CDATA[Polish Act on Industrial Property Law]]></category>
		<category><![CDATA[Polish courts]]></category>
		<category><![CDATA[Polish institutions]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Polish Patent Office]]></category>
		<category><![CDATA[Polish Supreme Administrative Court]]></category>
		<category><![CDATA[similarity of goods]]></category>
		<category><![CDATA[similarity of signs]]></category>
		<category><![CDATA[trade mark lapse]]></category>
		<category><![CDATA[trade mark opposition]]></category>
		<category><![CDATA[trade mark use]]></category>
		<category><![CDATA[trademark law]]></category>
		<category><![CDATA[Voivodeship Administrative Court]]></category>

		<guid isPermaLink="false">http://rychlicki.net/en/?p=7463</guid>
		<description><![CDATA[Nufarm Australia Limited, the owner of the trade mark DUAL SALT TECHNOLOGY R-164428 registered for goods in Class 5, requested the Polish Patent Office to decide on the lapse of the right of protection for DUAL IR-0534713 owned by Syngenta Participations AG. Earlier before, Syngenta opposed the registratin of the trade mark DUAL SALT TECHNOLOGY [...]]]></description>
		<wfw:commentRss>http://rychlicki.net/en/2012/01/17/7463/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trade mark law, case II GSK 56/10</title>
		<link>http://rychlicki.net/en/2011/03/25/6570/</link>
		<comments>http://rychlicki.net/en/2011/03/25/6570/#comments</comments>
		<pubDate>Fri, 25 Mar 2011 13:50:16 +0000</pubDate>
		<dc:creator>Tomasz Rychlicki</dc:creator>
				<category><![CDATA[Art. 132(2)(ii) IPL]]></category>
		<category><![CDATA[medicinal product]]></category>
		<category><![CDATA[Polish Supreme Administrative Court]]></category>
		<category><![CDATA[similarity of goods]]></category>
		<category><![CDATA[similarity of signs]]></category>
		<category><![CDATA[trade mark opposition]]></category>
		<category><![CDATA[trademark law]]></category>

		<guid isPermaLink="false">http://rychlicki.net/en/?p=6570</guid>
		<description><![CDATA[The Polish Patent Office registered the word trade mark TRIMEGAL R-177593 for Farmaceutyczna Spółdzielnia Pracy GALENA for goods in Class 5 such as pharmaceutical preparations. NOVARTIS AG filed a notice of opposition. The Swiss company claimed TRIMEGAL is similar to its trade mark TRILEPTAL IR-0560245 registered for goods in Class 5 such as pharmaceuticals. The [...]]]></description>
		<wfw:commentRss>http://rychlicki.net/en/2011/03/25/6570/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Advertising of pharmaceuticals, case VI SA/Wa 2110/09</title>
		<link>http://rychlicki.net/en/2010/03/17/3370/</link>
		<comments>http://rychlicki.net/en/2010/03/17/3370/#comments</comments>
		<pubDate>Wed, 17 Mar 2010 13:27:43 +0000</pubDate>
		<dc:creator>Tomasz Rychlicki</dc:creator>
				<category><![CDATA[Art. 52 PHL]]></category>
		<category><![CDATA[Main Pharmaceutical Inspector]]></category>
		<category><![CDATA[medicinal product]]></category>
		<category><![CDATA[pharmaceutical law]]></category>
		<category><![CDATA[pharmaceutical products advertising]]></category>
		<category><![CDATA[Polish Act on Pharmaceutical Law]]></category>
		<category><![CDATA[Voivodeship Administrative Court]]></category>

		<guid isPermaLink="false">http://rychlicki.net/en/?p=3370</guid>
		<description><![CDATA[On June 2009, the Polish newspaper Gazeta Wyborcza published an article (sort of an advertorial) containing images that depicted packagings of Stoperan and Septolete medicines, together with a note instructing that the leaflet attached to these products should also be read. The Main Pharmaceutical Inspector (MPI) ordered the immediate cessation of such actions in a [...]]]></description>
		<wfw:commentRss>http://rychlicki.net/en/2010/03/17/3370/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Advertising of pharmaceuticals, case II GSK 461/09</title>
		<link>http://rychlicki.net/en/2010/03/14/3317/</link>
		<comments>http://rychlicki.net/en/2010/03/14/3317/#comments</comments>
		<pubDate>Sun, 14 Mar 2010 00:25:48 +0000</pubDate>
		<dc:creator>Tomasz Rychlicki</dc:creator>
				<category><![CDATA[advertising law]]></category>
		<category><![CDATA[Art. 52 PHL]]></category>
		<category><![CDATA[Art. 57 PHL]]></category>
		<category><![CDATA[Main Pharmaceutical Inspector]]></category>
		<category><![CDATA[medicinal product]]></category>
		<category><![CDATA[pharmaceutical law]]></category>
		<category><![CDATA[pharmaceutical products advertising]]></category>
		<category><![CDATA[Polish Act on Pharmaceutical Law]]></category>
		<category><![CDATA[Polish Supreme Administrative Court]]></category>
		<category><![CDATA[trademark law]]></category>
		<category><![CDATA[Voivodeship Administrative Court]]></category>

		<guid isPermaLink="false">http://rychlicki.net/en/?p=3317</guid>
		<description><![CDATA[The Main Pharmaceutical Inspector (MPI) found that Polish Federation for Women and Family Planning (in Polish: Federacja na rzecz Kobiet i Planowania Rodziny) is publishing the names of contraceptives on its Internet website, and therefore the Federation advertises these products. The MPI ordered the immediate cessation of such actions because it may encourages the use [...]]]></description>
		<wfw:commentRss>http://rychlicki.net/en/2010/03/14/3317/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trade mark law, case II GSK 214/09</title>
		<link>http://rychlicki.net/en/2010/03/03/3164/</link>
		<comments>http://rychlicki.net/en/2010/03/03/3164/#comments</comments>
		<pubDate>Wed, 03 Mar 2010 14:27:52 +0000</pubDate>
		<dc:creator>Tomasz Rychlicki</dc:creator>
				<category><![CDATA[Art. 129(1)(ii) IPL]]></category>
		<category><![CDATA[Art. 129(2)(ii) IPL]]></category>
		<category><![CDATA[distinctive character]]></category>
		<category><![CDATA[generic sign]]></category>
		<category><![CDATA[medicinal product]]></category>
		<category><![CDATA[Polish Act on Industrial Property Law]]></category>
		<category><![CDATA[Polish Supreme Administrative Court]]></category>
		<category><![CDATA[trademark law]]></category>
		<category><![CDATA[Voivodeship Administrative Court]]></category>

		<guid isPermaLink="false">http://rychlicki.net/en/?p=3164</guid>
		<description><![CDATA[This is a continuation of the story described in a post entitled &#8220;Trade mark law, VI SA/Wa 1000/08&#8220;. Les Laboratoires Servier from France filed a cassation complaint. The Supreme Administrative Court in a judgment of 16 December 2009, case file II GSK 214/09, ruled that the sign GLAZIDE is representing a creative transformation of the [...]]]></description>
		<wfw:commentRss>http://rychlicki.net/en/2010/03/03/3164/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

